Literature DB >> 12381458

Neisseria meningitidis serogroup B: laboratory correlates of protection.

Clementien Vermont1, Germie van den Dobbelsteen.   

Abstract

Meningococcal disease in the Western countries is frequently caused by Neisseria meningitidis serogroup B. Major efforts have been made to develop a safe and efficacious vaccine against this serogroup which is suitable for use in infants and young children. To assess the quality of the immune response after vaccination with candidate vaccines, laboratory correlates of protection are needed. For serogroups A and C, serum bactericidal activity (SBA) is a well established predictor for protection, but for serogroup B other mechanisms besides SBA may also be involved in conferring protection from disease. Several laboratory methods for identification and evaluation of the immunogenicity of possible vaccine antigens are described in this review.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12381458     DOI： 10.1111/j.1574-695X.2002.tb00608.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN： 0928-8244


  14 in total

1.  T-cell-stimulating protein A elicits immune responses during meningococcal carriage and human disease.

Authors:  Karen Robinson; Karl G Wooldridge; Damien B Wells; Amal Hasan; Ian Todd; Adrian Robins; Richard James; Dlawer A A Ala'Aldeen
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

2.  The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate.

Authors:  Miao-Chiu Hung; Omar Salim; Jeannette N Williams; John E Heckels; Myron Christodoulides
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

3.  Recombinant protein truncation strategy for inducing bactericidal antibodies to the macrophage infectivity potentiator protein of Neisseria meningitidis and circumventing potential cross-reactivity with human FK506-binding proteins.

Authors:  Magdalena K Bielecka; Nathalie Devos; Mélanie Gilbert; Miao-Chiu Hung; Vincent Weynants; John E Heckels; Myron Christodoulides
Journal:  Infect Immun       Date:  2014-12-01       Impact factor: 3.441

4.  Development of immunity to serogroup B meningococci during carriage of Neisseria meningitidis in a cohort of university students.

Authors:  J Zoe Jordens; Jeannette N Williams; Graeme R Jones; Myron Christodoulides; John E Heckels
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

5.  Measurement of functional anti-meningococcal serogroup a activity using strain 3125 as the target strain for serum bactericidal assay.

Authors:  Jan T Poolman; Isabel De Vleeschauwer; Nathalie Durant; Nathalie Devos; Christiane Feron; Pascal Lestrate; Vincent Weynants; Dominique Boutriau
Journal:  Clin Vaccine Immunol       Date:  2011-05-18

Review 6.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

7.  Antiidiotypic DNA vaccination induces serum bactericidal activity and protection against group B meningococci.

Authors:  Concetta Beninati; Angelina Midiri; Giuseppe Mancuso; Carmelo Biondo; Milena Arigò; Elisabetta Gerace; Salvatore Papasergi; Maria Gambuzza; Mauro Boretti; Walter Magliani; Stefania Conti; Luciano Polonelli; Giuseppe Teti
Journal:  J Exp Med       Date:  2006-01-03       Impact factor: 14.307

8.  Evaluating Functional Immunity Following Encapsulated Bacterial Infection and Vaccination.

Authors:  Zheng Quan Toh; Rachel A Higgins; Nadia Mazarakis; Elysia Abbott; Jordan Nathanielsz; Anne Balloch; Kim Mulholland; Paul V Licciardi
Journal:  Vaccines (Basel)       Date:  2021-06-20

9.  Pathogen proteins eliciting antibodies do not share epitopes with host proteins: a bioinformatics approach.

Authors:  Isaac Amela; Juan Cedano; Enrique Querol
Journal:  PLoS One       Date:  2007-06-06       Impact factor: 3.240

10.  Vaccine Potential and Diversity of the Putative Cell Binding Factor (CBF, NMB0345/NEIS1825) Protein of Neisseria meningitidis.

Authors:  María Victoria Humbert; Miao-Chiu Hung; Renee Phillips; Charlene Akoto; Alison Hill; Wei-Ming Tan; John Edward Heckels; Myron Christodoulides
Journal:  PLoS One       Date:  2016-08-09       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.